Home Featured 2

Featured 2

Featured posts

Random

Milestones in Lung Cancer Treatment

lungcanc

Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?

Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication

Lung Cancer Global Mortality Projections Skyrocket for Women

Sublobar Resections for Early Lung Cancer

TTFields in Mesothelioma (The STELLAR Trial): More Stars Needed in the...

lungcanc

Evolution of Research Using Patient-Reported Outcomes in Lung Cancer: A Q&A...

lungcanc

On the Backs of Specialists: LDCT Screening Has Heightened the Importance...

lungcanc

KEYNOTE-010: Long-Term Outcomes and Results of Retreatment

lungcanc

Disparities in Meeting Eligibility Criteria for Lung Cancer Screening

lungcanc

Key Findings from the CAR T-Cell Study Presented at the 2019...

lungcanc

Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint...

lungcanc

Potential Improvement in Lung Cancer Deaths and Overall Mortality With Integration...

lungcanc

Smoking Cessation Prior to Lung Cancer Surgery

lungcanc

Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations...

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib